A clinical endocrinological quantitative study of specific symptomatic features among global type ii diabetic patients and a pharmacogenomic analysis of anti-diabetic pharmacotherapeutic agents

Introduction: The heterogeneity of type II diabetes mellitus manifestations depends on the subgroups of diabetes, the clinical variables, disease progression, genetic makeup and lifestyle factors; and this determines the response to treatment with novel glucose-lowering drugs, and lifestyle modifications
Objectives: The objective of this study is a clinical endocrinological quantitative analysis of specific symptomatic features among global type II diabetic patients, and a pharmacogenomic analysis of anti-diabetic pharmacotherapeutic agents.
Methods: The occurrence of specific symptoms among 25 new type II diabetes mellitus patients, and the detailed specific diabetic symptoms assessment, that is fatigue and polyuria, were recorded and graphically analysed with percentages, categorised according to their occurrences. A pharmacogenomic analysis of certain anti-diabetic pharmacotherapeutic agents was also conducted.
Results: among 25 patients, 9 patients had the symptom of fatigue, 3 patients had the symptom of polyuria, 3 patients had the symptom of both fatigue and polyuria, and 10 patients had neither fatigue, nor polyuria, as a symptom, that is, 36% of patients had fatigue, 12% of patients polyuria, 12% of patients had both fatigue and polyuria, and 40% of patients had neither fatigue, nor polyuria. The pharmacogenomic characteristics of the anti-diabetic pharmacotherapeutic agents were thoroughly analysed, which well-demonstrated their significance in their appropriateness in anti-diabetic type II treatment.
Conclusion: The diabetic symptom of fatigue was more predominant than polyuria. The anti-diabetic pharmacotherapeutic agents showed their pharmacogenomic efficacy.